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Purpose: The purpose of this study was to clarify the prognosis of cardiac resynchronization therapy with
deﬁbrillators (CRT-Ds) in Japan.
Methods: We selected 384 patients implanted with a CRT-D device from the observation database
(n¼1482) of the Japanese Cardiac Device Therapy Registry. We investigated the CRT criteria, including
the presence of New York Heart Association (NYHA) class III/IV symptoms, left ventricular ejection
fraction (LVEF) ≤35%, and QRS duration ≥120 ms. The patients were divided into 2 groups: the group
fulﬁlling all of the 3 criteria (Group A, n¼229) and the group not fulﬁlling the criteria (Group B, n¼155).
We compared mortality and appropriate shock rates between the 2 groups.
Results: There was no signiﬁcant difference in mortality (17.9% vs. 13.5%) or appropriate shock rates
(32.5% vs. 31.6%) during the observation period of 29.0715.7 months between the 2 groups. A logistic
multivariate analysis showed that appropriate shocks (hazard ratio [HR]¼1.85) and class III antiar-
rhythmic agents (HR¼2.33) were independently associated with all-cause death, and that age ≥70 years
(HR¼0.55), male gender (HR¼2.07), and presence of a single-chamber device (HR¼1.78) were
associated with appropriate shocks. The prognosis of Group A was better than that of the
COMPANION trial.
Conclusions: Japanese patients with CRT-D devices had a better prognosis than did those in the
COMPANION trial, but no signiﬁcant differences were observed between patients fulﬁlling and those
not fulﬁlling the above mentioned criteria.
& 2013 Japanese Heart Rhythm Society. Published by Elsevier B.V. All rights reserved.1. Introduction
Cardiac resynchronization therapy (CRT) with an implantable
cardioverter-deﬁbrillator (ICD) or without an ICD (CRT-P) is
recommended to reduce morbidity and mortality in patients
who have New York Heart Association (NYHA) class III/IV heartt Rhythm Society. Published by Els
t Committee of the Japanese
himizu).failure, are symptomatic despite optimal medical therapy, and
have a reduced left ventricular (LV) ejection fraction (LVEF) and
electrical dyssynchrony [1–3]. The effects of CRT are reﬂected
mainly by the degree and location of the dyssynchrony and by
the successful insertion of lead into the optimal LV lead site [4,5].
No signiﬁcant differences have been observed between the right
ventricular apical and non-apical positions of the lead tip in a
previous study [6].
In Japan, ICDs were approved by the Japanese Ministry of
Health, Labor and Welfare (MHLW) in 1996. CRT-P and CRT with
an ICD (CRT-D) were also approved in 2004 and 2006, respectively.evier B.V. All rights reserved.
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lished by the Japan Heart Rhythm Society for investigating the
actual conditions of implantable devices (ICD/CRT-D) [7]. New
guidelines were set forth by the Japanese Circulation Society in
2007 [8] and were then updated in 2011 [9].
The number of CRT-D implantations has markedly increased
since 2006 when they were approved by the MHLW. In particular,
primary prevention using CRT-D devices has dramatically
increased over the last 5 years in Japan according to the JCDTR
enrollment database [10], but this database has shown no sig-
niﬁcant changes in the criteria involving the QRS duration, LVEF,
and NYHA class in patients with a CRT-D device over these 5 years
[11]. Thus, the increase in the number of CRT-D device implanta-
tions for primary prevention did not result from an increase in the
number of patients with a relatively early phase of heart failure
and electrophysiologic disturbance in Japan [11].
The prognosis and occurrence of appropriate shocks in the
therapy for ventricular tachycardia/ventricular ﬁbrillation are not
clear in patients with implanted devices in Japan. Therefore, the
purpose of this study was to clarify the prognosis in patients who
were implanted with a CRT-D device in Japan.2. Methods
2.1. Patient population
Between January 1, 2006 and December 31, 2010, 384 patients
implanted with CRT-D devices were selected from 1482 patients
from the JCDTR observation database (ICDs and CRT-Ds) from 16
facilities of the Devise Assessment Committee of the Japanese
Heart Rhythm Society (JHRS) (Appendix). Data were collected by
means of a retrospective multicenter study. Informed consent was
waived for the analysis of preexisting clinical data.
The distribution of underlying heart disease in CRT-D patients
was investigated in the primary prevention and secondary pre-
vention groups. Underlying heart disease was classiﬁed into
ischemic heart disease (IHD), dilated cardiomyopathy (DCM),
secondary cardiomyopathy (2ndCM), hypertensive heart disease
(HHD), valvular heart disease (VHD), congenital heart disease
(CHD), hypertrophic cardiomyopathy (HCM), and miscellaneous
(micell).
The prognoses of the survival rate and appropriate shocks were
studied as the primary endpoints, and clinical variants associated
with mortality and appropriate shock rate were then investigated.
In this study, patients were divided into 2 groups according to the
CRT-D criteria (NYHA class III/IV symptoms, LVEF≤35%, and QRS
width ≥120 ms, as per the Japanese Circulation Society (JCS) 2011Fig. 1. Distribution of the underlying heart disease in the primary prevention and secon
prevention group; IHD: ischemic heart disease; DCM: dilated cardiomyopathy; 2ndCM:
disease; CHD: congenital heart disease; HCM: hypertrophic cardiomyopathy; micelle: mGuidelines [9]): Group A comprised 229 patients who fulﬁlled all
of the 3 criteria, and Group B comprised 155 patients who fulﬁlled
2 or fewer of the 3 criteria. Clinical characteristics, survival, and
appropriate shock rate were compared between the 2 groups.
In this study, a single-chamber ICD was deﬁned as an ICD with
no lead placed in the atrium. An appropriate shock was deﬁned as
shock therapy or antitachycardia pacing for ventricular tachycardia
and/or ventricular ﬁbrillation.
2.2. Statistical analysis
The data are presented as the mean7standard deviation (SD).
The chi-square test and Student t-test for independent variables
were used for comparisons between the groups. Kaplan–Meier
curves with survival rates and appropriate shocks as the outcomes
of interest were calculated. Further, the log-rank test statistic was
used to determine the statistical signiﬁcance of unadjusted differ-
ences in the time to the event. A univariate analysis (Mantel–
Haenszel method) of the clinical variables in the JCDTR question-
naire followed by multivariate analyses (linear model method) of
the clinical variables showing a signiﬁcant difference in the
univariate analysis were performed using the SPSS software (SPSS
16.0 Family for Windows, MapInfo, NY) for evaluating the associa-
tion with mortality and appropriate shocks in the CRT-D patients.
A value of po0.05 was considered statistically signiﬁcant.3. Results
3.1. Distribution of the underlying heart disease in the CRT-D
patients
A higher number of patients was present in the primary
prevention group (n¼247; 64%) than in the secondary prevention
group (n¼137; 46%), as shown in Fig. 1. The percentage of IHD
events was lower in the primary prevention group (19%) than in
the secondary prevention group (31%). On the other hand, the
percentage of CM events (DCM+2ndCM) was higher in the
primary prevention group (66%) than in the secondary prevention
group (54%). The percentage of IHD plus CM events in the primary
prevention group (85%) was similar to that in the secondary
prevention group (85%).
3.2. Clinical characteristics and medications
There were no signiﬁcant differences in age, percentage of
patients in the primary prevention group, and percentage of IHD
events and single-chamber CRT-D devices between Groups A anddary prevention groups. Primary: primary prevention group; secondary: secondary
secondary cardiomyopathy; HHD: hypertensive heart disease; VHD: valvular heart
iscellaneous.
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patients with NYHA class III/IV heart failure, lower LVEF, and wider
QRS duration in Group A than in Group B (p¼0.0001).
There was no signiﬁcant difference in the use of medications,
except for diuretics, ACE inhibitors, and class III antiarrhythmic
drugs, between the 2 groups (Table 2).3.3. Survival rate and appropriate shock rate
Thirty-eight patients in the primary prevention group and 24
patients in the secondary prevention group died during the
observation period of 29.0715.7 months. There was no signiﬁcant
difference in the survival rate between the primary and secondary
prevention groups (Fig. 2, left panel). The appropriate shock rate inTable 1
Clinical characteristics.
Group A
(n¼229)
Group B
(n¼155)
All
(n¼384)
p, Groups A
vs. B
Age 63712 61713 62713 0.117
Male (%) 158 (69) 114 (74) 272 (78) 0.198
Primary (%) 145 (63) 102 (66) 247 (64) 0.349
Underlying heart disease
IHD (%) 55 (24) 34 (22) 89 (23) 0.658
non-IHD (%) 174 (76) 121 (78) 295 (77)
NYHA class
I/II 0/0 19/94 19/94
(29%)
0.0001
III/IV 199/30 38/4 237/34
(71%)
LVEF (%) 2377 32712 27710 0.0001
QRS duration
(ms)
158727 142739 152733 0.0001
Single chamber
(%)
52 (23) 0 (0) 92 (24) 0.281
Primary: primary prevention of cardiac resynchronization therapy with deﬁbrilla-
tors (CRT-D); IHD: ischemic heart disease; non-IHD: non-ischemic heart disease;
NYHA: New York Heart Association; LVEF: left ventricular ejection fraction; single
chamber: single-chamber CRT-D.
Table 2
Medications.
Group A
(n¼229)
Group B
(n¼155)
All
(n¼384)
p, Groups A
vs. B
Diuretics (%) 192 (84) 102 (66) 294 (77) 0.0001
Spironolactone (%) 99 (43) 60 (39) 159 (41) 0.219
ACE (%) 102 (45) 53 (34) 155 (40) 0.027
ARB (%) 88 (38) 65 (42) 153 (40) 0.280
ACE and/or ARB
(%)
183 (80) 115 (74) 298 (78) 0.117
Beta-blockers (%) 180 (79) 111 (72) 291 (76) 0.074
Digitalis (%) 55 (24) 37 (24) 92 (24) 0.710
Nitrites (%) 19 (8) 10 (6) 29 (8) 0.321
Alpha-blockers (%) 0 (0) 0 (0) 0 (0) –
Antiarrhythmic agents
Class I
A (%) 1 (0.4) 3 (2) 4 (1) 0.307
B (%) 8 (3) 3 (2) 11 (3) 0.285
C (%) 1 (0.4) 0 (0) 1 (0.2) 0.596
Class II (%) 180 (78) 111 (72) 291(76) 0.074
Class III (%) 113 (49) 62 (40) 175 (46) 0.044
Class IV (%) 13 (6) 14 (9) 27 (7) 0.145
Statins (%) 55 (24) 37 (24) 92 (24) 0.537
Warfarin (%) 139 (61) 81 (53) 220 (57) 0.062
Antiplatelet
agents (%)
58 (25) 36 (23) 94 (24) 0.365
ACE: angiotensin-converting enzyme inhibitor; ARB: angiotensin II receptor
blocker; LVEF: left ventricular ejection fraction.the primary prevention group was 29.7% (n¼73), which was lower
than that in the secondary prevention group (36.5%, n¼50).
However, the difference did not reach statistical signiﬁcance in
the Kaplan–Meier curves (p¼0.213, Fig. 2, right panel).
Forty-one Group A patients (17.9%) and 21 Group B patients
(13.5%) died during the observation period (Fig. 3, left panel). The
survival rate after 40 months was worse in Group A than in Group
B, but no signiﬁcant difference was observed (p¼0.182) in the
Kaplan–Meier curves. Further, 74 Group A patients (32.5%) and 49
Group B patients (31.6%) received appropriate shocks during the
observation period (Fig. 3, right panel). The appropriate shock rate
after 40 months was higher in Group A than in Group B, but no
signiﬁcant difference was observed in the Kaplan–Meier curve
analysis between the 2 groups (p¼0.853).3.4. Clinical variants associated with mortality and appropriate
shocks in the CRT-D patients
None of the male patients, primary prevention group patients,
and patients with LVEF≤35%, NYHA class III/IV heart failure, and
QRS duration ≥120 ms showed any signiﬁcant association with all-
cause death; however, age ≥70 years, incidence of appropriate
shocks, S-creatinine level ≥1.5 mg/dl, use of class III antiarrhythmic
drugs, and presence of a single-chamber CRT-D showed signiﬁcant
association with all-cause death in the univariate analysis
(Table 3). Only incidence of appropriate shocks (hazard ratio
[HR]¼1.85, 95% conﬁdence interval [CI]: 1.04–3.28, p¼0.036)
and use of class III drugs (HR¼0.004, 95% CI: 1.32–4.13) were
independently associated with all-cause death (Table 3). Single-
chamber CRT-D devices had a tendency to be associated with all-
cause death (HR¼1.73; 95% CI: 0.94–3.19).
Primary prevention and presence of LVEF≤35%, NYHA class III/
IV heart failure symptoms, and QRS duration ≥120 ms did not
show signiﬁcant association with the incidence of appropriate
shocks; however, age ≥70 years, male gender, and presence of a
single-chamber CRT-D device showed a signiﬁcant difference in
the univariate analysis (Table 4). Only age ≥70 years (HR¼0.55,
95% CI: 0.33–0.91), male gender (HR¼2.07, 95% CI: 1.23–3.48), and
presence of a single-chamber CRT-D device (HR¼1.78, 95% CI:
1.08–2.93) were independently associated with appropriate shocks
in the CRT-D patients (Table 4).3.5. Comparison of the prognosis between the COMPANION trial [2]
and Group A from the JCDTR observation database
We compared the clinical characteristics between the Group A
patients from the JCDTR and patients from the COMPANION trial
(Table 5). There was no signiﬁcant difference in the percentage of
male subjects between the 2 studies. Although the percentage of IHD
events was signiﬁcantly higher (p¼0.0001) in the COMPANION trial
[2] than in Group A from the JCDTR, the ratios of the NYHA
classiﬁcation, LVEF, and QRS duration were similar between the
2 groups. For pharmacological therapy, angiotensin-converting
enzyme inhibitors and/or angiotensin II receptor blockers, loop
diuretics, and spironolactone were used more often in the COMPA-
NION trial than in Group A from the JCDTR. Beta-blockers were used
more in Group A from the JCDTR than in the COMPANION trial
(Table 5). All-cause death in Group A from the JCDTR was similar to
that in the COMPANION trial; however, the observation period for the
JCDTR was almost double that of the COMPANION trial. Therefore,
the annual mortality rate was better in Group A from the JCDTR
(3.5%/year) than in the COMPANION trial (7.4%/year).
Fig. 2. Survival rate and appropriate shock rate in the primary prevention and secondary prevention groups. Survival rate: rate of all-cause death; appropriate shock: shock
therapy for the treatment of ventricular tachycardia and ventricular ﬁbrillation.
Fig. 3. Survival rate and appropriate shock rate in Groups A and B. See Fig. 2 for the abbreviations.
Table 3
Clinical variants associated with mortality in patients with CRT-D.
Univariate analysis Multivariate analysis
HR 95% CI p HR 95% CI p
Age ≥70 years 0.50 0.26 – 0.99 0.042 0.57 0.29 – 1.13 0.108
Male 1.35 0.72 – 2.53 0.347
Primary 1.17 0.67 – 2.05 0.586
LVEF≤35% 1.34 0.58 – 3.13 0.493
NYHA III/IV 1.24 0.67 – 2.30 0.495
QRS duration ≥120 ms 0.62 0.30 – 1.29 0.199
IHD 0.84 0.45 – 1.58 0.592
Appropriate shock 2.10 1.21 – 3.65 0.008 1.85 1.04 – 3.28 0.036
S-creatinine ≥1.5 mg/dl 2.82 1.24 – 6.38 0.011 2.03 0.82 – 5.00 0.125
Class III drugs 2.32 1.32 – 4.06 0.003 2.33 1.32 – 4.13 0.004
Single chamber 1.81 1.00 – 3.26 0.046 1.73 0.94 – 3.19 0.080
HR: hazard ratio; CI: conﬁdence interval; Primary: primary prevention with CRT-D; LVEF: left ventricular ejection fraction; IHD: ischemic heart disease; S-creatinine: serum
creatinine; single chamber: single-chamber CRT-D.
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4.1. General considerations for CRT-D
CRT is known to improve LV systolic function, heart failure,
symptoms, quality of life, and prognosis in patients with moderateor severe heart failure, depressed systolic function, and a wide QRS
complex [1–3]. It is necessary to implant a CRT-D or ICD device in
patients with severe LV dysfunction, because CRT improves the
prognosis of patients. A meta-analysis of all-cause death and
admission rate showed no signiﬁcant difference between the use
of an ICD and use of a CRT-D device in patients with LV dysfunction
Table 4
Clinical variants associated with appropriate shocks in patients with CRT-D.
Univariate analysis Multivariate analysis
HR 95% CI p HR 95% CI p
Age≥70 years 0.54 0.33 – 0.88 0.013 0.55 0.33 – 0.91 0.020
Male 1.86 1.13 – 3.08 0.015 2.07 1.23 – 3.48 0.006
Primary 1.34 0.86 – 2.09 0.189
LVEF≤35% 1.60 0.82 – 3.11 0.164
NYHA III/IV 0.97 0.61 – 1.55 0.903
QRS duration≥120 ms 0.59 0.32 – 1.09 0.090
S-creatinine≥1.5 mg/dl 1.87 0.92 – 3.83 0.083
Class III drugs 1.23 0.73 – 1.73 0.585
Single chamber 1.79 1.10 – 2.91 0.018 1.78 1.08 – 2.93 0.024
HR: hazard ratio; CI: conﬁdence interval; Primary: primary prevention with CRT-D; LVEF: left ventricular ejection fraction; S-creatinine: serum creatinine; single chamber:
single-chamber CRT-D.
Table 5
Comparison of the clinical characteristics between the COMPANION and JCDTR
(Group A) trials.
n COMPANION JCDTR (Group A) p
CRT-D Therapy CRT-D Therapy
595 229
Age (years) 66 63 –
Male (%) 67 69 0.594
Ischemic heart disease (%) 55 24 0.0001
NYHA class III 86% 87% 0.751
LVEF (%) 22 23 –
QRS duration (ms) 160 158 –
Pharmacological therapy (%)
ACE 69 45 0.0001
ACE and/or ARB 90 80 0.0001
Beta-blockers 68 79 0.002
Loop diuretics 97 84 0.0001
Spironolactone 55 43 0.002
All-cause death, n (%) 105 (17.6) 41 (17.9) –
Follow-up (months) 15.7 29.0 –
–: Cannot be calculated; ACE: angiotensin-converting enzyme inhibitor; ARB:
angiotensin II receptor blocker; LVEF: left ventricular ejection fraction.
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patient groups implanted with ICD and CRT-D devices is unclear.
Some investigators concluded that CRT was not associated with a
decrease in the frequency of ventricular arrhythmias or appropriate
device therapies [13], and that CRT did not reduce the incidence of
atrial ﬁbrillation [14]. On the other hand, arrhythmia frequency and
the number of appropriate ICD treatments decreased after an
upgrade to a CRT-ICD device as a heart failure treatment. Thus, apart
from the hemodynamic beneﬁts, CRT may also ameliorate ventricular
tachyarrhythmia susceptibility in heart failure patients [15]. In a
recent study, after an upgrade from an ICD to a CRT-D device,
responders to CRT showed a trend toward a decrease in the
frequency of ventricular arrhythmias, and non-responders to CRT
showed a signiﬁcant increase in ventricular arrhythmias requiring
appropriate device therapy [16]. Further, CRT-D decreased the risk of
heart failure events in relatively asymptomatic patients with a low
ejection fraction and wide QRS complex [17–19].
CRT did not improve clinical outcomes or LV remodeling in
patients with an LVEF≤35% or symptoms of heart failure, but CRT
in patients with a QRS duration of o120 ms might be associated
with potential harm [20]. The ACC/AHA and ESC guidelines in
2008 postulated that CRT was recommended in patients with QRS
duration of ≥120 ms [21,22]. However, only a QRS duration
≥150 ms and a left bundle branch block (LBBB) pattern showed a
signiﬁcant difference in the prognosis between ICD and CRT-D
patients [17,18]. Presence of NYHA class II symptoms showed a
signiﬁcant difference in the prognosis between ICD and CRT-Dpatients [17–19]. The results of mega-trials related to CRT or CRT-D
had a strong inﬂuence on the guidelines for CRT-D/CRT-P. Accord-
ing to the 2011 Update from the Heart Failure Society of America
[23], CRT is recommended in patients who have a widened QRS
interval of ≥150 ms (changed from ≥120 ms, speciﬁed in the 2010
guidelines) that is not due to right bundle branch block (newly
added criterion) and who have persistent NYHA class II symptoms
(newly added criterion for biventricular pacing therapy recom-
mended in the 2010 guidelines). According to the 2012 ACCF/AHA/
HRS guidelines [24], CRT is indicated as class I for patients who
have an LVEF≤35%, sinus rhythm, LBBB with a QRS duration
≥150 ms, and NYHA class II, III, or ambulatory IV heart failure
symptoms: symptoms on guideline-directed medical therapy
(Level A for NYHA class III/IV; Level B for NYHA class II).
On the other hand, the 2011 update of the JCS guidelines [9]
stated that CRT is recommended in patients with LVEF≤35%, QRS
duration ≥120 ms, NYHA class III or ambulatory IV heart failure
symptoms despite optimal medical therapy, and sinus rhythm. In
the present study, the patients were divided into 2 groups on the
basis of whether they fulﬁlled the following 3 criteria: LVEF≤35%,
QRS duration ≥120 ms, and NYHA class III/IV heart failure symp-
toms, as speciﬁed by the JCS guidelines [9].
4.2. Actual conditions of the implantation of CRT-D devices in Japan
The number of CRT-D device implantations has increased
dramatically in not only Western and European countries but also
Japan [10]. Several reasons have been considered. First, much
evidence has proven that CRT-D/CRT-P improves prognosis in
patients with heart failure and severe LV dysfunction. Second,
CRT-D might be superior to CRT-P in improving prognosis and
decreasing sudden cardiac death. Several recent trials [17–19] have
also shown the potentially better effects of CRT-D, compared to
those of CRT-P, even in patients with early-stage heart failure.
However, the 3 criteria (QRS duration, LVEF, and NYHA classiﬁca-
tion) for CRT-P implantations have not changed over the last
5 years according to the JCDTR enrollment database in Japan.
Although primary prevention with CRT-D has increased over the
last 5 years in Japan, this has not resulted from an increase in
patients with a relatively early phase of heart failure and electro-
physiologic disturbance [11].
In a previous study of the distribution of underlying heart
diseases by routine clinical practice, the percentage of IHD events
was observed to be 62% in the Netherlands [25]. The percentage of
IHD events was 30% in the primary prevention group and 33% in
the secondary prevention group. On the other hand, in the present
study, the percentage of IHD events was 19% in the primary
prevention group and 31% in the secondary prevention group.
Thus, the percentage of IHD events in CRT-D patients is relatively
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result obtained with ICD use [10].
4.3. Survival rate and appropriate shock rate
In this study, no signiﬁcant difference was observed in the
survival rate for at least up to 40 months between patients who
qualiﬁed for CRT-D device implantation and those who did not. On
the other hand, no signiﬁcant difference was observed in the
survival rate between the primary prevention and secondary
prevention groups. However, in the real-world setting, this fact
does not seem surprising [25].
In a comparison with the COMPANION trial (13.5%/year), the
annual mortality rate in Group A of the JCDTR (7.4%/year) was
revealed to have a better prognosis. Some baseline variables that
differed in our patients would be expected to lead to worse
outcomes (an older age and higher percentage of ischemic
cardiomyopathy). These differences in the baseline characteristics
may partially explain the better survival rate in our patients as
compared with that in the COMPANION trial patients.
A single-center trial [23] in the USA also reported that survival
and cardiovascular hospitalization outcomes in the real-world
clinical setting are as good as, or better than, those demonstrated
in the COMPANION research trial [2]. They divided their patients
into 3 groups: group 1 (n¼429), standard indications; group 2
(n¼144), a subgroup of the group-1 patients who met the
COMPANION entrance criteria; and group 3 (n¼595), a cohort
both with and without a propensity-matching statistical analysis.
Survival was better in group 1 (annual mortality rate 8.5%) than in
group 3, but the mortality rates in the real-world setting were
similar to those in the COMPANION trial, once adjustments were
made for the differences in the baseline characteristics [23].
In a real-world registry [26] comprising 14,946 patients, the
annual mortality rate for any number of baseline characteristics,
including LVEF (24.7%), QRS duration (157 ms), beta-blocker use
(78.9%), and angiotensin-converting enzyme inhibitor and/or
angiotensin II receptor blocker use (74.2%), excluding age (73.0
years of age), was similar to that of our patients, whereas the
mortality rate at 3 years was 31.8% (10.6% per year). The authors of
that study concluded that the real-world mortality rates at 3–4
years after the CRT-D implantation appear to be higher than
previously recognized [26].
Between 1996 and 2010, from a total of 2859 patients with an
implanted ICD or CRT-D device at the Leiden University Medical
Center, The Netherlands, during a median follow-up of 3.4 years
(interquartile range, 1.7–5.7 years) [25], 107 (14%) primary preven-
tion ICD recipients, 253 (28%) secondary prevention ICD recipients,
and 302 (25%) CRT-D recipients died (all-cause death) [25]. The
annual mortality rate was 2.9% in the primary prevention ICD
patients, 4.5% in the secondary prevention ICD patients, and 6.9%
in the CRT-D patients. The annual mortality rate of these CRT-D
patients was slightly better than that of our patients.
In the present study, the annual rate of appropriate shocks in
the primary prevention group (12.3%/year) was better than that in
the secondary prevention group (15.1%/year), but this difference
was not statistically signiﬁcant in the Kaplan–Meier curves. There
was no signiﬁcant difference in the appropriate shock rate
between Group A (13.4%/year) and Group B (12.9%/year).
For instance, in 2134 ICD recipients (80% men; mean age,
63712 years) at the Leiden University Medical Center between
1996 and 2008 [27], the 5-year cumulative incidence of appro-
priate shocks was 20% (95% CI: 16–23%) in primary prevention
patients and was 37% (95% CI: 33–41%) in secondary prevention
patients. Secondary prevention patients exhibited more than
double the risk of appropriate shocks during the long-term
follow-up (HR: 2.3, 95% CI: 1.9–2.9; po0.001) [27]. The averageannual rate of appropriate shocks in patients who received
primary ICD therapy was 5.1% during 5 years of follow-up in the
Sudden Cardiac Death in Heart Failure (SCD-HeFT) Trial [28].
The annual rate of appropriate shocks was higher in our study
than in the Leiden University Medical Center data [27] and SCD-
HeFT Trial [28], because the clinical setting was worse in the CRT-
D patients than in the ICD patients. The CRT-D patients had more
severe heart failure and a wider QRS duration than did the ICD
patients.
4.4. Clinical variables associated with mortality and event rates
Many clinical variables such as the degree of heart failure, QRS
duration, QRS morphology, sex, lead placement, atrial ﬁbrillation,
and other patient selection criteria were associated with mortality
in the CRT-D patients. A recent study [23] postulated that a QRS
duration of ≥150 ms, LBBB, female gender, LV lead positioned at
sites other than the apical region, NYHA classes II–III and ambu-
latory IV heart failure symptoms, and sinus rhythm were strongly
associated with a better prognosis in CRT-D patients. In this study,
incidence of appropriate shocks and use of class III antiarrhythmic
drugs were independently associated with mortality in CRT-D
patients. Appropriate shocks have been known to worsen prog-
nosis in a previous study [29]. The reason underlying the poor
prognosis in patients using class III antiarrhythmic agents is
complex. The patients requiring class III antiarrhythmic treatment
had a substrate for lethal tachyarrhythmias related to appropriate
shocks, and that might have led to poor prognosis in the CRT-D
patients.
In the multivariate analysis in the present study, male gender
and a single-chamber ICD were independently associated with
appropriate shocks in CRT-D patients. Further, age ≥70 years had
an odds ratio of 0.55 (95% CI: 0.33–0.91). This led to a propensity
for cardiac events in the younger patients (o70 years old),
because younger patients had a more active lifestyle than did
the older patients. Although both men and women beneﬁt from
CRT, some data suggest that women may beneﬁt to a greater
degree than may men [17,30]. Additionally, women have experi-
enced greater improvements in echocardiographic measurements
of reverse remodeling [30]. A single-chamber ICD in this study was
deﬁned as an ICD with no lead placed in the atrium. We did not
determine whether single-chamber ICD implantation was due to
patients having paroxysmal, persistent, or permanent atrial ﬁbril-
lation or difﬁculty in the placement of the atrial leads. Thus, this
result indicates that dual-chamber ICDs have a better prognosis for
appropriate shocks than do single-chamber ICDs.
4.5. Limitations
This study was a multicenter, retrospective study that evalu-
ated all patients who underwent CRT-D device implantations at 16
hospitals. Many hospitals were university hospitals that might
have been actively involved in CRT-D research for many years and
might have developed a number of protocols devised to manage
patients treated with CRT-D devices. Thus, our ﬁndings may not
reﬂect the experience of the typical community-based CRT-D
programs in Japan. A larger multicenter, prospective study will
be necessary to determine more accurate information regarding
the actual conditions and prognosis of CRT-D treatment in Japan.5. Conclusions
Mortality was associated with appropriate shocks and use of
class III drugs, and appropriate shocks were associated with a
younger age, male gender, and single-chamber CRT-D devices.
A. Shimizu et al. / Journal of Arrhythmia 29 (2013) 168–174174Japanese patients with implanted CRT-D devices showed no
signiﬁcant differences in the prognosis irrespective of whether
the criteria were fulﬁlled. Japanese patients with implanted CRT-D
devices had a better prognosis than did those in the COMPANION
trial [2].Conﬂict of interest
The authors have no ﬁnancial conﬂicts of interest to disclose.Appendix
The hospitals participated in this study are given in alpha-
betical order.
Hiroshima University, Hokkaido University, Itabashi Central
Hospital, Jichi Medical University, Kitasato University, Kyorin
University, Nagoya University, National Cardiovascular Center,
Niigata University, Tokyo Women's Medical University, Tsukuba
University, University of Occupational and Environmental Health,
Okayama University, Osaka Medical University, Osaka City Uni-
versity, and Yamaguchi University.
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